The objective of drug repositioning is to apply existing drugs to different diseases or medical conditions than the original target, and thus alleviate to a certain extent the time and cost expended in drug development. Our system RESKO, REpositioning drugs using Side Effects and Knowledge from Ontologies, identifies drugs with similar side-effects which are potential candidates for use elsewhere, the supposition is that similar side-effects may be caused by drugs targeting similar proteins and pathways. RESKO, integrates drug chemical data, protein interaction and ontological knowledge. The novel aspects of our system include a high level of biological knowledge through the use of pathway and biological ontology integration. This provides a explanation facility lacking in most of the existing methods and improves the repositioning process. We evaluate the shared side effects from the eight conventional Alzheimer drugs, from which sixty-seven candidate drugs based on a side-effect commonality were identified. The top 25 drugs on the list were further investigated in depth for their suitability to be repositioned, the literature revealed that many of the candidate drugs appear to have been trialed for Alzheimer's disease. Thus verifying the accuracy of our system, we also compare our technique with several competing systems found in the literature.
Introduction
In this paper we demonstrate how adverse drug sideeffects can be used to identify potential candidates for drug repositioning for a variety of diseases. Drug repurposing or repositioning involves using existing pharmaceutical products for diseases or problems they were not specifically designed for. There are many advantages since off-the-shelf drugs have undergone extensive testing and their toxicological properties are well known, therefore the costs are greatly reduced and also time to product delivery [31] . Thus it is more economical to re-purpose an existing drug than develop one from scratch [16] . Difficulties in drug development arise because diseases are often complex with multi-factorial components such as interactions between genes, proteins and the environment [7] . Furthermore, drugs that are highly selective in terms of their targets are very rare. Many patients when taking a drug will experience unwanted side-effects as the medication may also also interact to varying degrees with non-target proteins [52] . However, this feature can be used to search for drugs with similar side-effects that might target the defective biological functions more effectively than conventional drugs. Since there is wealth of freely available drug and protein databases, drug repositioning is an ideal application area for knowledge based systems and computational statistics.
However, not all of the drug repositioning discoveries are through computational intelligence techniques. Interestingly, there are many examples where unanticipated side-effects have proven to be beneficial to patients suffering from unrelated problems to the original purpose of the drug thus allowing the drugs to be re-deployed [53] . The most often cited example is Sildenafil, a drug developed by Pfizer which was intended to treat heart problems by allowing better blood flow. It was discovered to have a particular side-effect on the male participants, it was later marketed as Viagra, the drug now has annual sales in excess of $1.6 Billion [1] . Other notable drugs such as the infamous Thalidomide that caused birth defects in the 1950s, has been redeployed to treat leprosy and multiple myeloma [45] .
A deeper understanding of the causes of disease is necessary, in particular knowledge of the genetic differences between individuals will eventually lead to improved treatments [40] . This has only recently been made possible by the development of advanced genomic and proteomic techniques which are able to provide detailed and accurate data on individual cellular processes [12] . We are The other sources of information include the gene ontology and the disease ontology. These provide expert level descriptions of biological functions, structures and the genes involved in the pathways targeted by the drugs and represent higher level knowledge. Furthermore, they provide an indication of similarity between diseases and links between shared genes and pathways. In this paper we extend previous work by incorporating chemical structure information from the Chemical European Molecular Biology Laboratory (CHeMbL) database [9] and also knowledge from the two main biological ontologies (gene and disease ontologies) to enhance biological understanding. Integrating ontologies within a larger system has been successfully implemented by researchers in the past [44, 29] .
The main technical challenge of our work is to integrate the disparate sources of data and knowledge in a principled way we use matrix algebra and a modified version of Zitniks data fusion scheme using matrix factorization, originally developed for integrating molecular data to discover disease-to-disease associations [60] . In Figure 2 each of the sources of data (chemical structure, protein interaction, gene ontology, diseases ontology and pathway information) are in matrix format, the ontology information is converted into separate matrices annotating the proteins, the overall relation matrix used for creating the complex network is very sparse. The equations and processes are explained in greater detail in the methods section.
The remainder of this paper is structured as follows. Section two reviews the related work and places the novelty of our methods into context; section three describes our methodology, the data and the algorithm's developed. Section four highlights the results with special emphasis on Alzheimer's disease and we compare our results with competing systems using other diseases. Finally, section five presents the conclusions along with future work.
Related work
In recent years a variety of computational methods have been applied to drug repositioning problems, we discuss the features and limitations of the most important systems. The PREdicting Drug IndiCaTions (PREDICT) system tackles the issue by building drug-to-drug similarities and disease-to-disease indications for personalized medicine [19] . The main limitation of PREDICT ..Θ 4 ) are integrated using matrix factorization. The large, sparse relation matrix is used to build complex networks. The latent network is derived from the adjacency matrix holding the complex network connectivity.
is that it lacks drug-to-target information which is necessary for understanding rational drug design and hence improves accuracy. The Connectivity MAP (CMAP) system was developed by compiling the data available from Affymetrix genechips [12] . CMAP integrates the eXtreme Sum (XSum) scoring algorithm which can identify druginteraction pairs, however the method lacks reliable validation data as some diseases had worse than random performance. A different approach was taken by the Guilt By Association (GBA) method [13] . GBA system mapped the diseases to one logical set and mapped the drugs to another set, the degree of overlap between the two sets was determined systematically. Only a small number of drug candidates could be verified and the false positive rate appears rather high and the system is potentially biased with better results for older drugs. The Similarity-based LArgemargin learning of Multiple Sources (SLAMS) method integrates several sources of data such as chemical structure and protein targets, chemical data is integrated through the creation of binary fingerprints [59] . SLAMS appears to outperform many competing repositioning but the authors conclude it may have a high false positive rate.
Other methods consider using graph network theory to integrate diverse data types and and provide statistical information. Detecting motifs of bi-cliques extracted from a drug-target-disease network can be achieved by integrating disease-to-chemical associations [14] . Motifs are statistically significant patterns of connections that represent a biologically relevant function or activity. The bicliques produced appear to have a high false positive rate through using only the complex networks structure. Another approach, the Heterogeneous Graph Based Inference (HGBI) method implemented a complex network analysis [49] . The complex network consisted of a triple layer of interconnected nodes using protein interaction and drug target data. The HGBI system was applied to diseases with no known drugs and was able to perform well by ranking drugs that have received attention in the clinical trials literature. Computational complexity may limit the HGBI system with the addition of further layers.
The multiple Drug information sources and multiple Disease information sources to facilitate drug Repositioning tasks (DRR) method is notable because it generates a list of proteins to be targeted by specific drugs using an omics based approach [57] . DDR used the Online Mendelian Inheritance In Man (OMIM) database to provide information on gene mutations and their frequencies to generate a candidate list of 524 Alzheimer's disease implicated proteins. Some were known from the literature and some were speculative. DDR is probably more accurate than most repositioning systems but lacks biological knowledge. The similarity Measures and BI-Random Walk (MBiRW) method uses an iterative procedure integrating a random walk to measure similarity of drugs and diseases [34, 35] . MBiRW incorporates novel similarity measures and is well validated against gold standard data but lacks target information and biologically relevant information. Other work on complex networks has revealed further insights into why drug similarity does not always account for identifying useful drugs for repositioning [20] . It is often the case that network evaluation of many diseases and drug pairs reveals how diseases and their drugs are clustered into neighborhoods of proximity, though it does not have the infrastructure to explain why. Other researchers has concentrated on applying various combinations of methods [33, 41, 53, 50, 32] .
The novel aspects of our work include a strong level of biological knowledge through the use of pathway and biological information ontology integration. This provides a level of understanding lacking in most of the existing methods and improves the repositioning process. Integration of biological knowledge enables the users to relate drugs to their side-effects and on/off protein targets. The disparate sources of data are integrated through the use of matrix factorization. We validate our work through the analysis of our top scoring drugs against evidence from the drug repurposing literature and compare our method against several of the most similar computational techniques. We use various statistical measures to assess and rank our drug candidates.
Methods
In the following discussions, reference should be made to Figure 3 for clarification of dataflow and processing. The stages required to produce a list of candidate drugs that exhibit potential to be re-purposed are:
• Determine disease of interest
• Search Drugbank for main conventional drug treatments
• Search SIDER4 for side-effects associated with each drug
• Obtain list of joint side-effects common to all treatments
• Use list to search SIDER4 for any drug sharing at least 50% of these side-effects
• Obtain chemical structures, protein interactions, biological pathways for these drugs
• Annotate proteins with gene and disease ontology terms
• Build matrices of annotations, chemical structures and proteins and integrate matrices
• Build a complex network, calculate statistics
• Convert graph into latent network, determine effects of latent variables
• Calculate ranking for each candidate drug
Data bases and sources of information
The initial starting point for using our system is to obtain the Unified Medical Language System (UMLS) code for the disease of interest. UMLS codes provide a unique ID for each disease and sub-disease, and is used to interrogate the DrugBank database to provide a list of known, conventional treatments. Drugbank contains the majority of drugs that are currently prescribed, or have been withdrawn or are at the clinical trial stage [28] . This resource is widely used by those developing drugs, chemists, pharmacologists and others involved in pharmaceutics research. Every drug is listed with its main targets, known off-targets along with chemical structure and other important characteristics.
Having obtained a list of conventional drugs used to treat the disease of interest, the SIDER4 database is accessed to give a list of side-effects for each drug [26] . SIDER4, an important repository of hundreds of drugs and thousands of their known side-effects on humans. This freely available database contains more than 1,430 drugs and 58,880 side effects. The information on the drugs is collected, from the national registries and charity organisations [27] . In addition to side-effects for the 1,430 drugs SIDER4 also has information on the frequency of their relative occurrence in patients. It should be noted that SIDER4 contains many more side-effects per drug than would normally appear in the packet-insert that is included in every drug prescription. We did not use any of the adverse effect ontologies such as Ontology Adverse Effects [22] . Although these ontologies could provide a deeper understanding of the relationship between treatments and side-effects, the pattern matching algorithm we used in algorithm 1 is sufficient for our purposes.
We removed from SIDER4, 10% of the most common side-effects that occur with most drugs such as Nausea, Dermatitis, Rash, Vomiting, Headache, Dizziness etc as per the work of Atias [3] . In total, 573 side-effect types were removed. Further preprocessing replaced lengthy drug/compound names with their drugbank identifiers. For example (10ALPHA,13ALPHA,14BETA,17AL-PHA)-17-HYDROXYANDROST-4-EN-3-ONE becomes DB07768.
Our basic proposition is that shared side-effects between the drugs used to treat a disease can be combined into a search pattern to interrogate the SIDER4 database again to identify candidate drugs causing similar side-effects. The assumption is that these drugs are targeting similar biochemical pathways (inadvertently) and therefore may be candidates for re-purposing to the original disease. The side-effects pertaining to the nine drugs commonly used to treat Alzheimer's Disease (AD), such as Donepezil, Galantamine and Rivastigmine were obtained from the SIDER4 database.
Once a list of new, candidate drugs has been generated and sorted according to their percentage side-effect similarity, other databases can be interrogated for chemical structure, protein targets and biological pathways relating to these drugs. These results are further enhanced by enrichment from gene ontology and disease ontology for biological plausibility.
The chemical structure of the candidate drugs was downloaded from CHemBL, this database contains chemical compounds represented as text data called the Simplified Molecular Input Line Entry System (SMILES) format [51] . We created a series of fingerprints for each drug based on atom-pair arrangements of 2048 bits in size. We consider the chemical structure of the candidate drugs useful information to assess their suitability for repositioning.
The candidate drugs have known on-target and offtarget proteins, this knowledge is augmented by accessing protein-to-protein interactions and drug/chemical to protein interactions found in the search tool for interactions of chemicals (STITCH) database [38] Figure 3 : Detailed step by step process diagram makes use of over six million known protein-to-protein interactions discovered by text mining and annotation by human experts [46] . Additionally, a further 30,000 associations are predicted based on similar protein characteristics using predictive data mining. These databases contains protein to chemical mappings and augments the information held in Drugbank which may not contain all the potential drug to protein interactions.
The Reactome database is accessed to provide indications of which biological pathways are involved with the on-target and off-target protein interactions affected by the candidate drugs [54] . Deeper insights can be gained into the biological functions by allowing users of the system to relate side-effects to drugs and then to the pathways. Individual proteins must not be regarded in isolation but seen as a system of interacting components. The associated pathways are incorporated into the overall drug ranking measure.
Searching for side-effect similarity
The work described in this paper extends the complex network and pattern matching algorithms previously developed by the authors [37] to include a novel data integration method that assesses the candidate drugs, their chemical characteristics, associated proteins and biological pathways as described in section 3.7.
Referring to algorithm 1, lines 2-7 perform the initialization of key values: to obtain the UMLS code for the disease of interest, for the minimum number of side-effects for a viable search to be conducted (set at ≥ 3), the number of conventional drugs currently treating this disease is set to zero and finally a percentage value of side-effects similarity for a candidate drug to be considered useful (set at 50%).
Lines 8-9 obtain the drugs currently treating the disease of interest. Lines 10-17 ensure that each conventional drug is annotated with a list of more than three or more sideeffects, if any drug has fewer than three side-effects it is discarded. The critical processing is performed by line 18 which creates a list of the side-effects common to all of the conventional drugs. This list of common side-effects is used by lines 19-25 to search SIDER4 and return any candidate drug that has at least one side-effect in the search list. The new list of repositioned candidate drugs is sorted by lines 26-27, in descending order and only those with greater than 50% similarity are returned from the function call.
Empirically, it was determined that conventional drugs with fewer than three side-effects are generally not useful as they tend to have either highly specific or overly common side-effects. They cannot provide a rich enough search pattern and these are pruned from the list of drugs. The common side-effects for the remaining conventional 
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Graph theory
We use graph theoretic methods to build networks of interacting proteins such as the drug on-targets and offtargets (where known). These networks provide various statistical measures describing the relationships between the interacting proteins and the candidate drugs, with some tentative indications of why a particular side-effect occurs. We incorporate these statistical measures into the overall integration mechanism, which contributes in ranking the drugs in terms of usefulness for repositioning. Graph creation and inferencing is usually through matrix algebra, edge lists are converted into connectivity matrices, we can define a graph G = (V, E) where the nodes also called vertices V containing links called edges E. In our application, we determine the relevance of protein connectivity patterns using criteria from the graph theoretic centrality statistics [17, 6] .
We use a number of commonly used graph-based measures to evaluate the protein networks. The closeness statistic (CC) provides a measure of how near each node is to every other node in the network. Some nodes may be more prominent than others due to their topology. The distance d(v i , v j ) from a given protein i to another j is generally characterized as the number of links in the shortest path between them, N is the number of all proteins (nodes) in the network. We define the closeness centrality of protein i:
The clustering coefficient (C i ) provides a local measure of modularity of the network in terms of shared components and interactions for each vertex. Thus a randomly connected network would have a very different coefficient to a biologically cohesive network [5] .
Where L i defines the number of links between k i neighbors of vertex i, k i is the degree (number of connections) of node i. The coefficient C i is bounded between 0 and 1.
The clustering coefficient for the entire graph is simply the average of the local clustering values C of each vertex C i for all nodes i = 1, ..., N .
Gene ontology
Gene ontology (GO) provides useful biological information and it is recognized as the de facto standard for gene product annotation [29] . For our purposes, we produce a binary matrix of proteins annotated with the presence or absence of terms. This enables an assessment to be made regarding the biological plausibility of the interacting proteins to observe the extent they actually cooperate in viable biological functions rather than random or spurious associations. For each protein associated with the candidate drugs enrichment was performed using gene ontology (GO), the enrichment is based on similarity measures using information content techniques. The content of which is calculated by taking the negative log probability of the terms t appearing in the database. A number of measures can be used to rank semantic similarity, we used the Wang criterion as it reflects the biological plausibility better than other measures because of the way semantic similarity of the GO terms are calculated, using both the locations of the terms in the GO graph and their relations with their ancestor terms [48] .
For the Wang equation, where S A(t) represents the Svalue of GO term t related to term A and S B(t) is the Svalue of GO term t related to term B, SV (A) and SV (B) are the semantic values of GO term A and B.
Drug chemical fingerprints
The chemical data held in the large SDF file is used to create a unique fingerprint for each drug. We used the Tanimoto similarity coefficient was to compare the chemical structure of our 77 drugs based on pairwise binary fingerprints [11] . The Tanimoto coefficient generally gives better results than other metrics. Equation 5 shows the generally accepted form of the Tanimoto coefficient.
where: N a is the number of unique fragments in the first compound and N b is the number of unique fragments in the second compound; N c is the shared amount of overlapping fragments. Thus we would expect to see drugs with similar chemical structures to have similar properties and medicinal effects.
Disease ontology
We integrated information from the Disease Ontology (DO) to annotate the drug targets and other proteins to obtain a deeper interpretation of the biological processes and structures [30, 43] . The DO database contains knowledge on 8,043 inherited, developmental and acquired human diseases. Through enrichment analysis, the R package DOSim is able to explore the biological meaning of related genes in terms of structure, function and hierarchy. The concepts in DOSim are organized into a directed acyclic graph (DAG) similar to a tree structure, the concepts are linked by' is-a' relationships. The lower the term or concept is positioned in the hierarchy then the more specific the term is, higher-up terms describe higher level or more abstract concepts. In order to identify biological themes the Hypergeometric model is used to assess the frequency of those semantic terms in a list and to determine whether the number of selected genes associated with disease is larger than expected than by chance alone.
Where N is the total number of genes present in the distribution, M is the number of genes within that distribution that are annotated (either through primary links or secondary links) to the node of interest, n is the size of the list of genes of interest and k is the number of genes within that list related to the node.
Data integration
Individually, each method of data analysis provides important information in a specific area, however, our systems strength comes from the integration of these disparate sources of knowledge in a principled way [8] .
where: R is the relation matrix used to construct the complex network, G identifies the drugs, S is the weighting factor for the drugs, G T is the transpose, Θ (t) represents the matrices containing the variables for PPI, drug structure, GO, DO and pathways.
Similarly, the G and S block matrix factors are structured and calculated by:
Model validation strategies
The large, integrated matrix network containing the protein to protein interaction network, the chemical data, pathway and ontologies is converted into a latent network model. The advantages for doing so include the ability to model latent variables in the form of vertex classes and thus perform classification metrics such as accuracy, true positive rate, false positive rate and allows for plotting of ROC curves and precision-recall curves. The modeling of variables that are generally unobserved but are likely to play a major role in vertex connectivity is motivated by the assumption that lack of covariate information allows the vertices's to be exchangeable in a principled way [24] . The disadvantage is that there are many possible configurations of networks and pair-specific effects. They are both implemented and validated through Bayesian methods using Monte Carlo Markov Chain techniques (MCMC) to simulate from the posterior distributions the model specification [25] .
In particular we use 10-fold cross-validation to test the goodness-of-fit, here the model is randomly divided into ten subsets of equal size and in each cross-validation trial one subset is taken for the test set while remaining nine folds comprise the training set [10] .
We define the latent variables U i as a set of vectors (U i , . . . , U iQ )
T , these formed from the adjacency matrix U from the complex network of protein-protein interactions, the pathways and ontologies. We build several such matrices to highlight different complexities of model (i.e. PPI only, PPI+Pathway,PPI+Pathway+Ontology,all data sources).
The MCMC eigenmodel [23] and shown in equation 8, simulates models from the relevant posterior priors, describing the influence of pairs of covariates X ij . A series of transformations convert the elements of a diagonal matrix giving the relative importance of each latent variable (U i ). The productÛ^Û holds the eigenvectors of the pairwise latent effects. In equation 8 where Y denotes class labels, X contains the covariates (e.g complex network connectivity), the effect of the latent variables is contained in U 1 ...U Nv , the probabilities for each vertex pair are represented by p ij . The process of generating the eigenmodels is validated by 10-fold cross-validation.
In equation 9 the notation of the three matrices where : U 11 indicates in U the simple index notation to access its elements, however in Λ implies a symmetric matrix and is expressed by multiset index notation U {{11}} . In matrix UΛÛ the elements are eigenvalues can be accessed by U {11} . The cross-validated eigenmodels enable predictions to be made on edge status to generate metrics for goodness of fit such as accuracy and precision to be assessed.
Ranking candidate drugs
The final data analysis phase is to rank and assess the list of candidate drugs, this is a two stage process. First, each candidate drug is individually compared with the conventional drugs using the generalized Jaccard coefficient (equation 10) which can manage continuous values.
Where: F (D j ) are the variables of interest, such as protein interactions, pathways, ontology annotation and chemical similarity shared between the candidate drugs and the conventional drugs F (D i ). This produces a matrix containing individual values for each drug. However, these need to be modified by the overall strength and effect of the variables, similar to coefficients in a regression equation. The second stage calculates the actual score given to each candidate drug by equation 11 which takes the difference for each candidate/conventional pair multiplied by theÛ^Û value for that variable.
The diagonal of the matrixÛ^Û contains the eigenvalues which we use as coefficients for the latent variables, these act as weights for the importance of the latent variables and are multiplied by the score index calculated from the Jaccard matrix. The candidates are then reevaluated using these scores and re-ranked according to their potential for repurposing.
Hardware and software platform
We implemented the system using the R language with the RStudio programming environment, on an Intel Xenon 64-bit CPU, using dual processors (3.2GHz) with six cores, and 128 GB of RAM. R is very extendable using packages written by other researchers [42] . We used the following R packages: GOSim [56] , DOSim [55] , ChemmineR [4] , eigenmodel [23] . Our R code and data files are freely available to all researchers on GitHub for download: https://github.com/kenmcgarry/DrugSideEffects
Results
The first stage is to obtain the UMLS code for our disease of interest (Alzheimer's), the code (C0002395) is used to automatically search drugbank for the list of drugs used to treat Alzheimer's disease, these are presented in table 1. We removed DB07701 as it is a new drug and lacks important information required for our method such as an Anatomical Therapeutic Chemical (ATC) code, commercial drug name and lacks literature based evidence. The remaining list of eight conventional treatments are used to search SIDER4 and returns all the side-effects associated with each drug. We then combine the side-effects jointly for the drugs. Figure 4 shows a Venn diagram illustrating the common side-effects, because of graphical limitations only five of the nine Alzheimer's drugs can be shown. The diagram indicates 10 common side-effects, however, using all nine drugs gives only eight common side-effects. The decision was made to tackle the problem by using only the sideeffects common to all eight drugs which meant that eight side-effects were available for this study. These shared side-effects were used to predict similar interactions which provided a list of 77 drugs, the criteria being a 50% cut-off point of shared side-effects. We only examined the first 25 drugs with the highest ranks. Table 2 lists all eight side-effects.
We decided to use the overlaps between the nine drugs as this allowed for 8 side-effects to be available for study, this simple approach proved to be quite powerful. Initial work on the side-effects and known-targets can be found in [37] . Anatomical Therapeutic Chemical (ATC) codes, the majority of the drugs are 'N', that is to say they are intended to target problems relating to the Nervous system. Some of the drugs have been used to treat the symptoms of Alzheimer's disease such as depression, anxiety etc. Some have actually been used with a view to halt the degenerative process. The candidate drugs at the lower end of our similarity scale such as Tramadol, an analgesic drug, affects the peripheral and central nervous system [39] . Tramadol, an opioid is mainly used to treat pain, in terms of Alzheimer's, patients are advised to avoid it, as it appears to worsen the condition. This is as it has anticholinergic side effects. It causes serious side effects like serotonin syndrome, this is due to the influx of the neurotransmitter serotonin and then it inhibits the reuptake of serotonin, which can cause toxic levels. This could be a possible reason for tramadol worsening the condition of Alzheimer sufferers. Side effects like confusion and agitation worsen for Alzheimer patients on tramadol, the effects seem to be severe in the elderly [47] .
Zolpidem actually appears to be implicated with causing dementia when underlying diseases, such as hypertension and diabetes after controlling for potential confounders, such as age, sex, coronary artery disease, diabetes and anti-hypertension drugs are taken into account. In table 4 for 10 of our candidate drugs we have presented for each drug up to five of the original diseases and symptoms they were designed to treat. On average each drug was used to treat 21 diseases/indications, the minimum was one disease and the maximum value was 88 diseases.
Analysis of the chemical structures and protein targets
A computational model was built using the chemical data from drugbank, this indicates the connectivity pat- terns linking drug to target receptors. We downloaded the relevant structure data files (SDF) for the 77 drugs (69 candidate drugs and 8 current drugs) using their drugbank identifiers, The atom-pairs are converted into molecular fingerprints and these are clustered.
We created a chemical fingerprint for each of the drugs, we chose 2048 atom-pairs although it is possible to use a structure containing 4096 most common atom pairs in DrugBank. The pairwise distances are calculated for all 77 entries (69 candidate drugs and 8 current drugs) between the given fingerprints and then fit a Beta distribution to the resulting Tanimoto scores, conditioned on the number of set bits in each fingerprint. The highest matching drug is similarity is Pergolide with a 35% commonality. The majority of drugs have between 32% and 25% chemical similarity. Since these all these candidate drugs had similar side-effects and since their chemical composition is quite different, we can conclude that chemical similarity alone should not be used to seek out drugs for re-purposing.
Using hierarchical clustering on the drug similarity matrix provides a little bit more information. Through a process trial and error we deduced that there are 10 clusters. The validity of clusters in terms of composition is more or less confirmed by the similarity matrix. However, analysis of the chemical similarity matrix does not provide a full explanation and further integration of data is needed.
The silhouette plot in Figure 5b indicates that the majority of the drug clusters are reasonably good in terms of quality of fit. Values near one (unity) indicates that the observation is well placed in its cluster; values near zero show that it's likely that an observation should belong to some other cluster.
• 0.71-1.0 -A strong structure has been found • 0.51-0.70 -A reasonable structure has been found • 0.26-0.50 -The structure is weak and could be artificial
• < 0.25 No substantial structure has been found
The chemical information must be collated with higher level biological knowledge and known protein interactions for a deeper and more accurate indication of the usefulness of the candidate drugs. However, we examine the next set of results from a drug centric viewpoint. The drugs designed to combat diseases are targeted at specific proteins but unfortunately also affect off-targets and create side-effects. Furthermore, proteins tend to operate together in modules that perform specific functions and that proteins can belong to several modules. It is therefore essential to build up a complete profile of the drugs and their interaction partners.
Complex network analysis of drug to protein connectivity patterns and biological pathways
Diagrams are of limited use when displaying connectivity patterns of complex networks, even the small networks can easily become incomprehensible and visually are of limited use. The network statistics based on the values of hubness, closeness and betweeness provide a deeper understanding of the connectivity patterns than a visual assessment. The protein targets and known protein interactions of the 25 drugs were identified, downloaded from the relevant database (STITCH) and complex network analysis was applied to the subsequent network structures. We created 25 separate protein-to-drug interaction networks and calculated the relevant statistics for each and then combined the 25 networks into one large interaction network and recalculated the statistics.
The statistics for the top 25 drug networks is shown in table 5, every network has individual values for each protein (not shown) in terms of hubness and betweenness. The number of edges, number nodes, the modularity, and average path will be identical for each protein in a given network. It should be stated that these networks are both off and on-targets and the data is from STITCH. In Figure  8 we display the drug network patterns, where drugs are denoted by triangle and proteins by circles. Protein targets colored in yellow are common to two or more drugs. The protein targets that have common drugs implies they affect common pathways, this will be the reason for the common or shared side-effects.
The pathways presented in table 6 show 20 of the 50 pathways identified, these play a role in a number of important cellular and metabolic processes, when this pathway annotation is integrated with the other drug-to-protein networks we are able to discern a number of overlapping functions and processes. Observing the enrichment process we can see that proteins implicated with the same disease (and related diseases) are more predisposed to interact with each other rather than interact with other proteins. These proteins also have common GO terms and are likely to be located in the same tissues. Proximity, in protein-protein networks as borne out by the network statistics is an important factor. Disease genes appear to high degree but low clustering coefficients. Although drugs act at the level of protein/enzyme interactions, their overall effect is to modify the cells processes or signaling mechanisms that comprise important biological pathways. A biological pathway can be described as a collection of ordered, discrete actions among molecules that can breakdown proteins or assemble them in the cell. Such a pathway can trigger the assembly of new molecules by turning genes on and off. There are several types of pathways that control metabolism, signaling cascades, transport and otherwise generally control the behavior and actions of the cell in response to stimuli. The normal healthy body requires the coordination of many biological pathways, the majority of diseases involve the malfunction of proteins that cooperate in pathways. In fact 30% of drugs operate on one type of protein called G-protein-coupled receptors (GPCRS).
Disease similarity analysis using the gene and disease ontology
For each of the 77 drugs we note the disease/symptoms each one is targeted against and produce a correlation matrix from the terms annotating each disease from the disease ontology. Observing the correlation values (using Wang similarity measure) we can see the terms are reasonably similar between Parkinson's and Alzheimer's disease. In Figure 7 the main types of diseases treated by the 77 drugs are shown. The similarity measure is constrained to lie between 0 and 1, with 1 being the highest level of similarity. Ignoring the diagonal, the highest measure is between psychosis and schizophrenia (0.64) and between Parkinson's and Alzheimer's (0.44), depression and psychosis (0.39), followed by epilepsy and Alzheimer's (0.35). Estimation of correlational strength is based on Cohen's measures where very high 0.9 -1.0; high 0.7 -0.9; moderate 0.5 -0.7 ; low 0.3 -0.5.
Overall, we find 48 DO terms used to describe the diseases in a hierarchy. Through extensive cross-mapping of DO terms to standard clinical and medical terminologies such as the Medical Subject Headings (MeSH), the International Classification of Diseases (ICD), Systematized Nomenclature of Medicine (SNOMED) and Online Mendelian Inheritance in Man (OMIM), can reflect the current knowledge of human diseases and their associations with phenotype, environment and genetics. In table 7 the 48 terms assigned to the 10 diseases are shown, in addition to exact matches the Wang measure also assesses the semantic similarity.
The protein networks can be further enhanced by integrating known biological knowledge from gene ontology [2, 15] . This information illuminates biological pathways, signaling mechanisms, genes, associated diseases that the proteins are involved in and indicates where the drug of interest is active. The information is important since the drug will often interact with off-targets, identifying these interactions will often lead to an explanation of why a drug has particular side-effects.
In table 8 a sample of GO terms assigned to the proteins affected by the candidate drugs is presented. The terms are as we would expect given they relate mainly to the central nervous systems and neuronal functioning. The proteins are a mixture of planned targets and off-targets, that is to say the drugs have inadvertently targeted some proteins. This is part of the reason why side-effects occur.
Data integration, model accuracy and drug scoring
The sources of data are merged in a principled way using the matrix factorization scheme scheme described in equation 7. Based on the linear equation the sources of data were each allocated a coefficient (similar to regression) and a matrix was produced for each drug and latent variable in the network. The diagonal contains the combined eigenvalue for each drug, the Jaccard index was calculated for variable also and used as a weight or coefficient. This was used to reevaluate the initial list of candidate drugs as determined by side-effect similarity alone. Referring to table 9, the initial ranking (table 3) determined by side-effect similarity alone has changed somewhat. Ropinirole is still the top scoring drug but the positions of the majority of the drugs has changed and the last three drugs were not on the original list of 25 having moved up the list.
As a measure of confidence, we validated our findings from the latent network [25] . In the left hand-side of Figure  6 we plot the ROC curves for the latent network. We use eigenmodels with 5-fold cross-validation using MCMC to simulate the posterior distributions. We take the typical values of 10,000 for burn-in and 1,000 for inferencing. This allows us to model the effects of using: 1. protein and drug interactions alone, 2. protein interactions + pathways, 3. protein interactions + pathways + level 2 ontology. The Area under the Curve (AUC) for the three models are 75%, 88% and 93% respectively. Increasing the amount of information provides the complex network with greater, internal robustness.
Generally, all complex networks can be validated like classifiers either between networks (comparing different networks) or within a single network (predicting internal connections) [25] . The latent network is validated by classifying the connections as belonging to individual nodes in the graph. Several subsets are sampled through 5-fold cross-validation, at each step the non-sampled section of the network is predicted and class accuracy determined and displayed using receiver operating characteristic curves (ROC) and precision-recall (PR) curves. The ROC is based on evaluating the tradeoffs between specificity and sensitivity. Specificity is the probability of predicting that a link exists between two nodes given the correct situation is indeed a link, whereas sensitivity is the probability of predicting no link exists between two nodes given the true state is indeed no such link exists.
In Figure 6 the precision-recall (PR) curves are presented, these diagrams indicate the precision values for corresponding sensitivity (recall) values. The PR plot presents a global evaluation of the network model. Should a high area under the curve exists, this represents both high recall and high precision. High precision implies a low false positive rate, and high recall suggests a low false negative rate. Large values for both criteria, indicate that the classifier is providing good results (high precision), as well as returning a majority of all positive results (high recall).
Comparison with other drug repositioning techniques
In table 10 we compare our results with three competing methods from the literature, Zhang [59] , Wang [49] and Gottlieb [19] . With the exception of Wang, all the authors have provided a ranking.
Our highest ranking drug is Ropinirole and does not appear in the other systems. Selegiline appears as the top drug for Zhang's system and is ranked as 4th top drug for our system. The highest ranked drug for the Wang system is Lorazepam, which does not appear in any of the other systems. The top ranked drug for Gottlieb system is Amantadine, this is ranked by our system as 34th and by Zhang's system as 3rd ranked. Interestingly, Carbidopa was filtered out of our system since we did not have access to its ATC code -Zhang's system places this drug as ranked 2nd and Gottlieb's system places it as 8th. However, upon replacing it back in our database and rerunning the tests (ignoring chemical structure and lack of ATC code) Carbidopa is picked up by our system with a raw side-effect similarity score of 28%. The only other occurrence of drugs appearing in our system as Wang's is Pergolide. An earlier version of our system had a greater similarity with Wang's candidate drugs, however when we filtered out drugs with many common side-effects, and focused on fewer, more specific side-effects, Olanzapine and other drugs disappeared from our list.
Analyzing other diseases
In order to be assured of the robustness of our approach we tackle several other diseases using our system. Referring to the related work we analyze three other diseases that have been investigated for the potential to re-purpose current drugs. These results are displayed in table 11.
We examined Rheumatoid Arthritis and compared our results with Zhang [58] , who obtained different results to us but we both had identified Imatinib as a potential candidate that had received attention from a clinical trial. The next disease was Systemic Lupus Erythematosus, which we compared with Zhang's other work [59] . Our third scoring drug is in fact a class of drugs (Conjugated Estrogens) of which Leflunomide is an example identified by Zhang, this appears in our lists but with a similarity of 33% and would not technically be considered. We compared the results of Non Small Cell Lung Cancer (NSCLC) with those of Wang [49] . Virtually all of our top ranked drugs had been the attention of multiple clinical trials. Out of Wang's top drugs; Cisplatin, Carboplatin, Methotrexate and Temozolomide, only Cisplatin and Temozolomide were identified by our system at 33% similarity.
Discussion
Empirically, by using a smaller number of highly specific side-effects we discovered a more valid (based on evaluating the literature) list of drugs for repurposing. There is however, a trade-off between the number of current drugs used in the initial search and the potential for returning either many or very few side-effects. Our system requires diseases with at least two drugs as a certain 'critical mass' of common side-effects (for the disease) need to be present.
Furthermore, if the initial side-effect database is not preprocessed by removal of common side-effects then many useless candidate drugs will be returned in the search, as common side-effects such as dizziness and nausea are experienced by almost all drugs and thus are unhelpful. On the other hand, using more than 10-15 drugs in the initial side-effect search is unlikely to lead to side-effects common to all. Our top scoring drug (Ropinirole) is used to treat Parkinson's, restless legs and shaking conditions. It is a dopamine receptor agonist drug and there is research to suggest it has a neuro-protective effect. We used the research literature to verify if the candidate drugs identified by our system had any potential for repositioning. Several, in addition to Ropinirole have been the subject of clinical trials but the results have been mixed.
We conducted several literature based comparisons between our system and the related methods. The differences uncovered between the various drug re-purposing systems simply reflects the different methods of data integration and types of data used. Although, no methods produced exactly the same list of candidates, their top scoring candidates were drugs that had been the focus of clinical trials. Indeed, the various algorithms must be considered complementary in terms of candidate identification. The use of ontology's has provided our system with knowledge at a higher level than protein interactions and chemical structures. The information provided by the ontology's help reduce the false positive rate (FPR), as seen by the ROC/PR, without this information the FPR tends to increase with unsuitable drugs being identified as potential candidates.
Conclusions
Drug repositioning is a viable and useful process to augment and complement the work already accomplished in drug development. We have presented a novel method that can successfully identify useful candidates for drug repositioning by integrating high level knowledge from several ontology's, this ability is currently lacking in most competing methods. We have validated its predictive ability by cross-validation and have used several disease case studies. For the case study investigating Alzheimer's disease, the majority of the 25 candidate drugs exhibited the potential to be repurposed as a treatment for Alzheimer's. A few have been tested clinically and the results confirm they can reduce the level of new plaque formation. About three or four candidate drugs are actually implicated in causing/exacerbating dementia. Clearly, these drugs are targeting the correct pathways/mechanisms but their drug to protein interactions are harmful. Other drugs examined in research and clinical trials, exhibited the potential to improve behavioral psychosis, agitation and other behavioral symptoms associated with Alzheimer's.
Some of the drugs we examined are in early research stages or have only been tested in animal models, or have just entered clinical trials. Our methods have a number of limitations we hope to address in future work. For example, the process of detecting common side-effects is achieved through an iterative process of randomly splitting the list of current treatment drugs by 50% if no common side-effects are found. An optimization solution using a search algorithm or meta-heuristic would improve this process. A likely avenue for future work would be to model and predict potential side-effects for new and experimental drugs using additional resources such as the Ontology for Adverse Effects. We also intend to improve the expert system front-end, providing a more conventional explanation facility to describe the joint pathways and shared target proteins. Despite the limitations, the majority of the research studies examined supported our hypothesis of using side-effects to identify candidate drugs for the first stage in drug repurposing.
